448
Participants
Start Date
January 15, 2022
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
Adalimumab and its biosimilars
"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
Biological: Etanercept and its biosimilars
"1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection"
Golimumab
"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
Infliximab biosimilar
"1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection"
Collaborators (1)
Linical Korea
INDUSTRY
Hanyang University Seoul Hospital
OTHER